Choose from a list of different products offered within the KILR platform to support your immuno-oncology drug discovery and development journey. These products include bioassay kits, effector cells, stable cell lines, cell pools, and retroparticles for use in screening applications and relative potency testing in lot-release programs. Consider ready-to-use bioassays with different immune effectors cells like PBMCs, NK cells, or KILR Effector Cells for potency or lot-release testing. Use KILR Effector Cells in any ADCC assay to measure target cell death. With stable cell lines and cell pools, select the relevant tumor model and study the Fc-mediated effector functions of your therapeutic antibody. Or, generate your own stable KILR cell pools/lines with retroviral particles that can transduce almost any cell line.
To obtain custom KILR cell lines, cell pools, or assays, contact custom development capabilities.
The KILR platform is based on the industry-validated Enzyme-Fragment Complementation (EFC) technology. EFC is based on two recombinant β-galactosidase (β-gal) enzyme fragments that act as an enzyme acceptor (EA) and an enzyme donor (ED). Separately, the fragments are inactive, but when combined, they form an active β-gal enzyme that hydrolyzes its substrate to produce a chemiluminescence signal.